Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04623541
What this trial is testing

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Who this might be right for
Relapsed/Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's Syndrome+1 more
Genmab 194
Early research (Phase 1)Looking for participantsNCT04221542
What this trial is testing

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Amgen 479
Early research (Phase 1)UnknownNCT03463928
What this trial is testing

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Who this might be right for
B Cell Leukemia
Chinese PLA General Hospital 10
Testing effectiveness (Phase 2)Study completedNCT06266091
What this trial is testing

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Who this might be right for
Malignant Ascites
Wuhan YZY Biopharma Co., Ltd. 115
Not applicableApproved For MarketingNCT05733650
What this trial is testing

Expanded Access Program for Epcoritamab

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+2 more
Genmab
Large-scale testing (Phase 3)Looking for participantsNCT07221253
What this trial is testing

Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Who this might be right for
Biliary Tract Cancer
AstraZeneca 1,100
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 304
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Testing effectiveness (Phase 2)Ended earlyNCT04844073
What this trial is testing

TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Who this might be right for
Squamous Cell Cancer of Head and Neck (SCCHN)Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer
Takeda 95
Early research (Phase 1)UnknownNCT05442996
What this trial is testing

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor, Adult
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)WithdrawnNCT03524261
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Study completedNCT03929666
What this trial is testing

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Who this might be right for
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals 74
Early research (Phase 1)Looking for participantsNCT07612176
What this trial is testing

NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc. 155
Testing effectiveness (Phase 2)Study completedNCT00560794
What this trial is testing

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH 21
Early research (Phase 1)Active Not RecruitingNCT05675449
What this trial is testing

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 59
Early research (Phase 1)Ended earlyNCT05817058
What this trial is testing

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Affimed GmbH 30
Early research (Phase 1)Not Yet RecruitingNCT06015568
What this trial is testing

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Who this might be right for
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Betta Pharmaceuticals Co., Ltd. 172
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849610
What this trial is testing

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Who this might be right for
High-Risk de Novo Multiple Myeloma
PETHEMA Foundation 30
Early research (Phase 1)Looking for participantsNCT06410131
What this trial is testing

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16

Who this might be right for
Solid Tumors
Sound Biopharmaceuticals Ltd. 68
Next Page